{"entity":"novo-nordisk","id":"ent_novo-nordisk","name":"Novo Nordisk","wikidata":"Q818846","page":"https://asof.is/record/novo-nordisk","summary":"Novo Nordisk is a Danish pharmaceutical company, headquartered in Bagsvaerd Denmark. Its CEO is Maziar Mike Doustdar, since 2025. It reported revenue of 309.06B DKK for the period ended December 31, 2025.","title":"Novo Nordisk: CEO Maziar Mike Doustdar","key_facts":[{"label":"CEO","value":"Maziar Mike Doustdar","note":"since 2025","claim":"clm_09DBC29C37EF"},{"label":"Chair","value":"Lars Rebien Sørensen","claim":"clm_572A7A46A90E"},{"label":"Headquarters","value":"Bagsvaerd Denmark","claim":"clm_71389B010ACD"},{"label":"Revenue","value":"309.06B DKK","recorded":"309,064,000,000 DKK","note":"to 2025-12-31","claim":"clm_8F7EC31D7FFC"},{"label":"Employees","value":"69,505 employee","note":"as of 2025-12-31","claim":"clm_8EB909BEF688"},{"label":"Ticker","value":"NVO · NYSE","claim":"clm_A89E46223B59"}],"faq":[{"question":"Who is the CEO of Novo Nordisk?","answer":"Maziar Mike Doustdar, since 2025, as the AsOf record states with its sources."},{"question":"Where is Novo Nordisk headquartered?","answer":"Bagsvaerd Denmark."},{"question":"What is Novo Nordisk's revenue?","answer":"309.06B DKK for the period ended December 31, 2025."}],"as_of":"2026-11-09","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/novo-nordisk/ceo","md":"https://asof.is/record/novo-nordisk/ceo.md","json":"https://asof.is/v1/entities/novo-nordisk/ceo"},{"predicate":"chair","page":"https://asof.is/record/novo-nordisk/chair","md":"https://asof.is/record/novo-nordisk/chair.md","json":"https://asof.is/v1/entities/novo-nordisk/chair"},{"predicate":"headquarters","page":"https://asof.is/record/novo-nordisk/headquarters","md":"https://asof.is/record/novo-nordisk/headquarters.md","json":"https://asof.is/v1/entities/novo-nordisk/headquarters"},{"predicate":"employees","page":"https://asof.is/record/novo-nordisk/employees","md":"https://asof.is/record/novo-nordisk/employees.md","json":"https://asof.is/v1/entities/novo-nordisk/employees"},{"predicate":"revenue","page":"https://asof.is/record/novo-nordisk/revenue","md":"https://asof.is/record/novo-nordisk/revenue.md","json":"https://asof.is/v1/entities/novo-nordisk/revenue"},{"predicate":"net_income","page":"https://asof.is/record/novo-nordisk/net_income","md":"https://asof.is/record/novo-nordisk/net_income.md","json":"https://asof.is/v1/entities/novo-nordisk/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/novo-nordisk/operating_income","md":"https://asof.is/record/novo-nordisk/operating_income.md","json":"https://asof.is/v1/entities/novo-nordisk/operating_income"}],"products":[],"coverage":{"entity":"novo-nordisk","name":"Novo Nordisk","kind":"organization","sources":[{"source":"wikidata","item":"Q818846","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":353278,"ticker":"NVO","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":55,"open":19,"retracted":0,"first":"1923-01-01","predicates":{"listed_on":{"claims":2,"open":2,"kind":"fact"},"total_assets":{"claims":6,"open":1,"kind":"fact"},"ceo":{"claims":1,"open":1,"kind":"fact"},"operating_income":{"claims":7,"open":1,"kind":"fact"},"net_income":{"claims":7,"open":1,"kind":"fact"},"total_equity":{"claims":8,"open":1,"kind":"fact"},"employees":{"claims":7,"open":1,"kind":"fact"},"ticker":{"claims":2,"open":2,"kind":"identifier"},"revenue":{"claims":7,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"chair":{"claims":1,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":53,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":2,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_09DBC29C37EF","predicate":"ceo","value":"Maziar Mike Doustdar","valid_from":"2025-08-07","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ceo: Maziar Mike Doustdar\", as of 2025-08-07. Claim clm_09DBC29C37EF, https://asof.is/claim/clm_09DBC29C37EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm.","url":"https://asof.is/claim/clm_09DBC29C37EF","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","tier":"primary","publisher":"SEC EDGAR 20-F","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"On 7 August 2025, Maziar Mike Doustdar succeeded Lars Fruergaard Jørgensen as president and chief executive officer of Novo Nordisk.","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm"}},{"id":"clm_572A7A46A90E","predicate":"chair","value":"Lars Rebien Sørensen","valid_from":null,"undated":true,"valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk chair: Lars Rebien Sørensen\", undated. Claim clm_572A7A46A90E, https://asof.is/claim/clm_572A7A46A90E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm.","url":"https://asof.is/claim/clm_572A7A46A90E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm","tier":"primary","publisher":"SEC EDGAR 20-F","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"The chair of the Foundation’s board of directors (Lars Rebien Sørensen) serves as the chair of Novo Nordisk A/S’ board of directors.","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm"}},{"id":"clm_52A9D25B5082","predicate":"cik","value":"0000353278","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk cik: 0000353278\", undated. Claim clm_52A9D25B5082, https://asof.is/claim/clm_52A9D25B5082, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_52A9D25B5082","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8EB909BEF688","predicate":"employees","value":"69,505 employee","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 69,505 employee\", as of 2025-12-31. Claim clm_8EB909BEF688, https://asof.is/claim/clm_8EB909BEF688, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8EB909BEF688","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"},{"url":"https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0","tier":"secondary","publisher":null,"published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_A875D9470529","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk fiscal year end: 12-31\", undated. Claim clm_A875D9470529, https://asof.is/claim/clm_A875D9470529, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_A875D9470529","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_71389B010ACD","predicate":"headquarters","value":"Bagsvaerd Denmark","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk headquarters: Bagsvaerd Denmark\", undated. Claim clm_71389B010ACD, https://asof.is/claim/clm_71389B010ACD, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_71389B010ACD","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_AECDFCB7C547","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk listed on: NYSE\", undated. Claim clm_AECDFCB7C547, https://asof.is/claim/clm_AECDFCB7C547, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_AECDFCB7C547","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_07286C13C782","predicate":"listed_on","value":"OTC","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk listed on: OTC\", undated. Claim clm_07286C13C782, https://asof.is/claim/clm_07286C13C782, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_07286C13C782","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F536BDE429B7","predicate":"net_income","value":"102,434,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 102,434,000,000 DKK\", as of 2025-12-31. Claim clm_F536BDE429B7, https://asof.is/claim/clm_F536BDE429B7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_F536BDE429B7","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_672756B8F8A9","predicate":"operating_income","value":"127,658,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 127,658,000,000 DKK\", as of 2025-12-31. Claim clm_672756B8F8A9, https://asof.is/claim/clm_672756B8F8A9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_672756B8F8A9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_5C5C98A60302","predicate":"registrant_name","value":"NOVO NORDISK A S","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk registrant name: NOVO NORDISK A S\", undated. Claim clm_5C5C98A60302, https://asof.is/claim/clm_5C5C98A60302, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_5C5C98A60302","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8F7EC31D7FFC","predicate":"revenue","value":"309,064,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 309,064,000,000 DKK\", as of 2025-12-31. Claim clm_8F7EC31D7FFC, https://asof.is/claim/clm_8F7EC31D7FFC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8F7EC31D7FFC","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_52574002BF9D","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_52574002BF9D, https://asof.is/claim/clm_52574002BF9D, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_52574002BF9D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A89E46223B59","predicate":"ticker","value":"NVO","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ticker: NVO\", undated. Claim clm_A89E46223B59, https://asof.is/claim/clm_A89E46223B59, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_A89E46223B59","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2B51766EA897","predicate":"ticker","value":"NONOF","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk ticker: NONOF\", undated. Claim clm_2B51766EA897, https://asof.is/claim/clm_2B51766EA897, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278.","url":"https://asof.is/claim/clm_2B51766EA897","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_BCB17EC648AA","predicate":"total_assets","value":"542,902,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 542,902,000,000 DKK\", as of 2025-12-31. Claim clm_BCB17EC648AA, https://asof.is/claim/clm_BCB17EC648AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_BCB17EC648AA","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_51EBABE50856","predicate":"total_equity","value":"194,047,000,000 DKK","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 194,047,000,000 DKK\", as of 2025-12-31. Claim clm_51EBABE50856, https://asof.is/claim/clm_51EBABE50856, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_51EBABE50856","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2025, filed 2026-02-04"}},{"id":"clm_F171E5861BC9","predicate":"website","value":"https://www.novonordisk.com","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk website: https://www.novonordisk.com\", undated. Claim clm_F171E5861BC9, https://asof.is/claim/clm_F171E5861BC9, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q818846.","url":"https://asof.is/claim/clm_F171E5861BC9","accessed":"2026-11-09"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Novo Nordisk.","url":"https://www.novonordisk.com"}},{"id":"clm_C639BE305784","predicate":"x_username","value":"novonordisk","valid_from":"2010-09-23","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk x username: novonordisk\", as of 2010-09-23. Claim clm_C639BE305784, https://asof.is/claim/clm_C639BE305784, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q818846.","url":"https://asof.is/claim/clm_C639BE305784","accessed":"2026-11-09"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q818846","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/novonordisk","url":"https://www.novonordisk.com"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}